Palvella Therapeutics (PVLA) announced that it will expand SELVA, the Company’s Phase 3 clinical trial of QTORIN 3.9% rapamycin anhydrous gel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback